Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.60
+0.31121.06%
Post-market: 29.660.0591+0.20%19:30 EDT
Volume:5K
Turnover:139.63K
Market Cap:55.35M
PE:- -
High:29.66
Open:29.08
Low:29.08
Close:29.29
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.44
T/O Rate:0.25%
Dividend:0.41
Dividend Rate:1.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection

Reuters
·
Sep 30

Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028

THOMSON REUTERS
·
Sep 30

Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection

THOMSON REUTERS
·
Sep 30

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Sep 30
More